📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Omalizumab for severe atopic dermatitis in 4- to 19-year-olds: the ADAPT RCT (2022)

First Author: Chan S

Attributed to: A randomised placebo-controlled study examining the role of anti-IgE in severe recalcitrant paediatric atopic eczema funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.3310/wcxn5739

PubMed Identifier: 35679442

Publication URI: http://europepmc.org/abstract/MED/35679442

Type: Journal Article/Review

Parent Publication: Efficacy and Mechanism Evaluation

Issue: 5